(ALB) Albemarle - NYSE
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 19.590m USD | Total Return: 173.6% in 12m
Avg Turnover: 368M
Qual. Beats: 1
Rev. Trend: -91.7%
Qual. Beats: 2
Warnings
Interest Coverage Ratio 0.5 is critical
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader, Confidence
Albemarle Corporation is a global specialty chemicals manufacturer headquartered in Charlotte, North Carolina. The company operates through three primary business segments: Energy Storage, Specialties, and Ketjen. As a critical supplier in the lithium-ion battery supply chain, Albemarle produces lithium carbonate and hydroxide essential for electric vehicle (EV) batteries, power grids, and consumer electronics.
The Specialties segment focuses on bromine-based solutions and high-purity lithium products for fire safety, pharmaceuticals, and aerospace applications. Its Ketjen segment provides catalysts to the petrochemical industry to improve refinery efficiency and fuel cleanliness. In the specialty chemicals sector, business models are often defined by high barriers to entry due to the technical complexity of extraction and the capital-intensive nature of chemical processing facilities.
The global energy transition has fundamentally shifted the demand profile for lithium, moving it from a niche industrial material to a strategic commodity linked to automotive electrification. Investors can gain deeper insights into these market dynamics by exploring the data tools on ValueRay. Albemarle’s diversified portfolio across bromine and catalysts provides a cash-flow buffer against the historical price volatility of the lithium market.
- Lithium market price volatility directly impacts revenue and profit margins
- Global electric vehicle adoption rates drive long-term lithium demand volume
- Lithium spodumene production costs and joint venture structures influence earnings
- Bromine specialty chemical demand fluctuates with global consumer electronics cycles
- Capital expenditure requirements for capacity expansion affect free cash flow profiles
| Net Income: -232.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 4.73 > 1.0 |
| NWC/Revenue: 30.63% < 20% (prev 42.46%; Δ -11.83% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.08b > Net Income -232.9m |
| Net Debt (895.1m) to EBITDA (747.1m): 1.20 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.6m) vs 12m ago 0.85% < -2% |
| Gross Margin: 18.53% > 18% (prev 3.49%; Δ 15.04% > 0.5%) |
| Asset Turnover: 34.19% > 50% (prev 29.96%; Δ 4.23% > 0%) |
| Interest Coverage Ratio: 0.48 > 6 (EBIT TTM 92.3m / Interest Expense TTM 191.8m) |
| A: 0.11 (Total Current Assets 3.26b - Total Current Liabilities 1.58b) / Total Assets 15.1b |
| B: 0.32 (Retained Earnings 4.84b / Total Assets 15.1b) |
| C: 0.01 (EBIT TTM 92.3m / Avg Total Assets 16.1b) |
| D: 1.96 (Book Value of Equity 9.85b / Total Liabilities 5.03b) |
| Altman-Z'' = 3.87 = AA |
| DSRI: 0.76 (Receivables 659.5m/807.9m, Revenue 5.49b/5.09b) |
| GMI: 0.19 (GM 3.49% / 18.53%) |
| AQI: 1.05 (AQ_t 0.22 / AQ_t-1 0.21) |
| SGI: 1.08 (Revenue 5.49b / 5.09b) |
| TATA: -0.09 (NI -232.9m - CFO 1.08b) / TA 15.1b) |
| Beneish M = -3.88 (Cap -4..+1) = AAA |
As of June 20, 2026, the stock is trading at USD 160.35 with a total of 4,385,400 shares traded.
Over the past week, the price has changed by +1.07%,
over one month by -8.52%,
over three months by -3.06% and
over the past year by +173.60%.
Albemarle has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold ALB.
- StrongBuy: 6
- Buy: 3
- Hold: 17
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 214.5 | 33.8% |
P/E Forward = 16.2602
P/S = 3.5654
P/B = 2.5725
P/EG = 1.0168
Revenue TTM = 5.49b USD
EBIT TTM = 92.3m USD
EBITDA TTM = 747.1m USD
Long Term Debt = 1.81b USD (from longTermDebt, last quarter)
Short Term Debt = 74.6m USD (from shortTermDebt, last quarter)
Debt = 1.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 103.1m
Net Debt = 895.1m USD (calculated: Debt 1.98b - CCE 1.09b)
Enterprise Value = 20.5b USD (19.6b + Debt 1.98b - CCE 1.09b)
Interest Coverage Ratio = 0.48 (Ebit TTM 92.3m / Interest Expense TTM 191.8m)
EV/FCF = 35.49x (Enterprise Value 20.5b / FCF TTM 577.3m)
FCF Yield = 2.82% (FCF TTM 577.3m / Enterprise Value 20.5b)
FCF Margin = 10.51% (FCF TTM 577.3m / Revenue TTM 5.49b)
Net Margin = -4.24% (Net Income TTM -232.9m / Revenue TTM 5.49b)
Gross Margin = 18.53% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.48b) / Revenue TTM)
Gross Margin QoQ = 35.06% (prev 14.20%)
Tobins Q-Ratio = 1.35 (Enterprise Value 20.5b / Total Assets 15.1b)
Interest Expense / Debt = 9.66% (Interest Expense 191.8m / Debt 1.98b)
Taxrate = 8.46% (21.5m / 254.2m)
NOPAT = 84.5m (EBIT 92.3m * (1 - 8.46%))
Current Ratio = 2.07 (Total Current Assets 3.26b / Total Current Liabilities 1.58b)
Debt / Equity = 0.20 (Debt 1.98b / totalStockholderEquity, last quarter 9.85b)
Debt / EBITDA = 1.20 (Net Debt 895.1m / EBITDA 747.1m)
Debt / FCF = 1.55 (Net Debt 895.1m / FCF TTM 577.3m)
Total Stockholder Equity = 9.91b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.45% (Net Income -232.9m / Total Assets 15.1b)
RoE = -2.35% (Net Income TTM -232.9m / Total Stockholder Equity 9.91b)
RoCE = 0.79% (EBIT 92.3m / Capital Employed (Equity 9.91b + L.T.Debt 1.81b))
RoIC = 0.63% (NOPAT 84.5m / Invested Capital 13.4b)
WACC = 12.82% (E(19.6b)/V(21.6b) * Re(13.22%) + D(1.98b)/V(21.6b) * Rd(9.66%) * (1-Tc(0.08)))
Discount Rate = 13.22% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 0.47%
[DCF] Terminal Value 61.47% ; FCFF base≈577.3m ; Y1≈579.7m ; Y5≈614.0m
[DCF] Fair Price = 38.45 (EV 5.43b - Net Debt 895.1m = Equity 4.54b / Shares 117.9m; r=12.82% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.46 | # QB: 1
Revenue Correlation: -91.69 | Revenue CAGR: -25.11% | SUE: 1.30 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.07 | Chg30d=+2.90% | Revisions=+50% | Analysts=17
EPS next Quarter (2026-09-30): EPS=3.40 | Chg30d=+4.14% | Revisions=+50% | Analysts=16
EPS current Year (2026-12-31): EPS=12.00 | Chg30d=+3.94% | Revisions=+73% | GrowthEPS=+1619.1% | GrowthRev=+18.9%
EPS next Year (2027-12-31): EPS=12.08 | Chg30d=+5.11% | Revisions=+73% | GrowthEPS=+0.6% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +73%